Introduction
============

Telomeres are specialised hexanucleotide repeats complexed to proteins. They are located at ends of linear chromosomes and protect their structural integrity[@B1]. Telomere length reduces with increasing chronological age and with accumulation of age-related comorbidities. Given that telomere shortening contributes to cellular senescence, telomere length represents a cellular marker of biological aging. A large number of studies suggest that telomere length is a marker of cancer risk and short leukocyte telomere length are believed to be causative events in malignant transformation[@B1].

The hypothesis that estrogen influences telomere length came from several preclinical, observational and interventional studies[@B2].This phenomenon was explained by the finding that estrogen stimulates telomerase via estrogen response element present in the TERT promoter region. Additional protective effect of estrogen on telomere length is thought to be mediated through its reduction in oxidative stress[@B3]. Despite the well-known antioxidant role of estrogen, estrogen metabolites, on the other hand, may paradoxically lead to increased oxidative stress through the formation of depurinating DNA adducts and release of surplus amount of superoxide radicals[@B4]. Several single nucleotide polymorphisms (SNPs) within the estrogen metabolic pathway have been described to have functional effects on the corresponding enzymes, thereby compromising conjugation and redox buffering capacity of cells[@B5]. Candidates include *CYP1B1*, which catalyze the conversion of estrogens to reactive catechol estrogens. Furthermore, we described that a *CYP1B1* SNP rs1056836 was significantly associated with biochemical recurrence after radical prostatectomy and relative *CYP1B1* mRNA expression[@B6].

Encouraged by such findings we have now tested *CYP1B1* SNPs for associations with risk of PCa in a case-control study. In addition, a real-time PCR based telomere assay was performed to investigate whether leukocyte telomere was in relation to *CYP1B1* SNPs.

Materials and Methods
=====================

Study Design and Population
---------------------------

The study subjects were mostly from previously published case-control study[@B7]. Briefly, 1115 eligible patients recruited into this study were newly diagnosed and histopathologically confirmed primary prostate adenocarcinoma from Fudan University Shanghai Cancer Center (FUSCC) between January 2005 and January 2012, of whom 1015 (92%) agreed to participate in this study. All cases had received no prior chemotherapy or radiotherapy upon recruitment. The tumor stage was determined according to criteria established by the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) classification system \[AJCC Staging Manual, sixth edition, 2002\]. Histopathological grading of the specimens was performed according to the Gleason score system. The clinical information including Gleason score, serum PSA level at diagnosis and disease stage were abstracted from the archival medical records. In addition, 1143 age-(± 5yr) and geographical regions-matched cancer-free ethnic Han Chinese controls were recruited from the Taizhou longitudinal (TZL) study conducted during a similar time period. TZL study was a large prospective cohort initiated to explore the environmental and genetic risk factors for common non-communicable diseases. Individuals with a known test of serum PSA \> 4 ng/mL present with or without abnormal digital rectal examination were excluded from the control group and those without response to the study participation were excluded (n = 91). All of the participants were interviewed with a questionnaire after a written informed consent was obtained. Blood samples were collected and processed as a routine practice by the FUSCC Tissue Bank (for cases) and the TZL study (for controls). This study was approved by the Institutional Review Board of FUSCC.

SNP Selection and Genotyping
----------------------------

Tagging SNPs were selected in the *CYP1B1* gene using the Tagger algorithm with r^2^ ≥ 0.8, and minor-allele frequencies \> 0.05 based on the HapMap population data for Han Chinese in Beijing. There were 9 tagging SNPs (rs1056836, rs10916, rs162562, rs2551188, rs9341250, rs9341266, rs9341248, rs162549, rs1056827).

All these nine SNPs were genotyped by the TaqMan real-time PCR method as described previously[@B8], [@B9]. Briefly, DNA isolation was performed by using the Qiagen Blood DNA Mini KIT (Qiagen Inc., Valencia, CA) with the buffy-coat fraction of the blood samples donated by the participants. The results with \> 99% call rates and 100% concordance for duplicated specimens were acceptable for further genotyping data analysis. SNP rs9341248 was removed because it did not conform to Hardy-Weinberg equilibrium (HWE) (P \< 0.05). Thus, a total of 8 SNPs were included for subsequent analysis.

Measurement of Relative Telomere Length
---------------------------------------

Relative telomere length measurements were available in 426 patients as described previously[@B9]. Briefly, telomere length as represented by the telomere repeat copy number to single copy gene (i.e., *36B4*) copy number (T/S) ratio was measured using real-time quantitative PCR method on an Applied Biosystems 7900HT. The PCR reaction mixture consisted of SYBR Green Mastermix (Applied Biosystems), 100 nmol/L Tel-1, 900 nmol/L Tel-2, 400 nmol/L 36B4d, 400 nmol/L 36B4u, and 7ng of genomic DNA. The thermal cycling profile was 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and at 56°C (for telomere) or 58°C (for *36B4*) for 1 min. Following amplification, a dissociation curve confirmed the specificity of the reaction. During each run, negative and positive controls, a calibrator DNA sample, and a standard curve were included. For each standard curve, 2-fold serial dilutions of a reference DNA sample were used to produce a standard curve in each reaction. Two main steps were involved in telomere length quantification: first, the T/S ratio was determined for each sample based on the standard curve. Second, the ratio for each sample was normalized to the calibrator DNA to standardize sample values across all reaction plates. The laboratory personnel were blinded to disease status. R^2^ for each standard curve was ≥ 0.99.

Statistical Analysis
--------------------

For all subjects, the χ^2^ test was used to assess differences in the frequency distributions of the selected demographic variables and genotypes of 8 SNPs between the cases and controls. The HWE for genotype distribution in controls was tested by a goodness-of-fit χ^2^ test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by univariable and multivariable unconditional logistic regression models to evaluate associations between the genotypes and risk of PCa without and with adjustment for confounding factors, respectively. Further stratification analyses were conducted to calculate the associations of SNP genotypes with PCa risk by demographic and clinicopathologic variables, followed by the homogeneity Q-tests. Spearman rank correlation was used to investigate associations between telomere length and age. Telomere length was categorized into dichotomies, tertile and quartile based on the distribution. To account for chance associations from multiple comparisons, we used the false-positive report probability (FPRP) to assess the false-positive association findings. All statistical analyses were performed with SAS software (version 9.1; SAS Institute, Cary, NC).

Results
=======

Characteristics of the study subjects
-------------------------------------

The distributions of demographic characteristics of the subjects are shown in **Table [1](#T1){ref-type="table"}**. Briefly, there were no statistical differences in the distributions of age and smoking status between two groups.

Associations of *CYP1B1* SNPs with PCa Risk
-------------------------------------------

The genotype frequencies of 8 *CYP1B1* SNPs and their associations with PCa risk are summarized in **Table [2](#T2){ref-type="table"}**. The observed genotype frequencies of 8 SNPs in controls agreed with the Hardy-Weinberg equilibrium. Furthermore, the genotype distribution of *CYP1B1* rs1056836 was significantly different between the cases and controls. . In multivariate logistic regression analysis, *CYP1B1* rs1056836 was associated with PCa risk. Compared with CC genotype, rs1056836 variant CG/GG genotype was associated with a decreased risk of PCa (OR: 0.80, 95% CI = 0.66-0.97). However, no associations between the other 7 SNPs and PCa risk were observed.

In the stratified analysis, the decreased risk was also observed in men who were ever smokers, Gleason score ≥7 (4 + 3), and stage III/IV (**Supplementary Table [1](#SM0){ref-type="supplementary-material"}**). Further homogeneity tests suggested, however, that there were no differences in the risk estimates between these strata.

Genetic variations and telomere length
--------------------------------------

To investigate whether the telomere length had prognostic significance, 426 patients were categorized into dichotomies, tertile and quartile based on their telomere length distribution (range, 0.06-2.06) (**Supplementary Table [2](#SM0){ref-type="supplementary-material"}**). Telomere length was inversely associated with age (r = -0.40, *P* \< 0.001). When participants were dichotomized according to the median telomere length value, significant differences in telomere length by genotype of *CYP1B1* rs1056836 and rs10916 were observed (**Table [3](#T3){ref-type="table"}**). Longer telomere length showed a significantly higher proportion of the CG/GG genotypes, compared with that of the CC genotype (OR: 1.60, 95% CI: 1.04-2.45).

FPRP Values for Associations between PCa Risk and*CYP1B1* SNPs
--------------------------------------------------------------

The FPRP values at different prior probability levels for all significant findings are summarized in the Supplementary Table [3](#SM0){ref-type="supplementary-material"}. When the assumption of prior probability was 0.01, no association was noteworthy in all subgroups for rs1056836 as well as rs10916. In contrast, some greater FPRP values for the other significant associations between *CYP1B1* variants and PCa risk suggested some possible false-positive results in the findings, which need further validation in larger studies.

Discussion
==========

In the current study we found a *CYP1B1* inherited variation rs1056836 associated with PCa risk and further showed its biologic association with leukocyte telomere length. Findings on *CYP1B1* polymorphisms and susceptibility to PCa have proved inconsistent across different ethnic groups[@B8]-[@B14]. However, previous studies were conducted in small-sized populations, and require confirmation in larger studies.

The SNP rs1056836 is a non-synonymous polymorphism in exon 3, which encodes the heme binding domain, and results in a G-to-C and subsequent amino acid substitutions of Valine-to-Leucine[@B15].The SNP has documented functional consequences on transcription, protein structure, and enzyme action[@B16], [@B17]. A number of studies have reported a decreased risk of PCa for carriers of the rs1056836 G allele, but the results were inconsistent in different ethnic groups. Meta-analysis results showed that rs1056836 is significantly associated with PCa susceptibility among Asians[@B18], [@B19] and our findings support this association. These inconclusive results may have several causes. First, it may result from the distribution of allele frequencies among different ethnicities or between different case sources. We found that the frequency of rs1056836 G allele was significantly lower in Asian controls than in Caucasian or mixed population controls. Second, the sample sizes of the cases and controls in the Asian populations were both noticeably smaller than those in Caucasians or mixed population subjects[@B18], [@B19]. The current study has sufficient power confirm the positive associations in Asians. Moreover, the mechanism of PCa development is similar to other cancers and is dependent on the interactions of genetic factors and environmental agents[@B20]. Environments and lifestyles are very different among individuals of different races. Thus, the aetiology of PCa is unlikely to be explained solely by genetic polymorphisms because hereditary variation alone cannot affect the risk of any disease. *CYP1B1* rs1056836 was associated with *CYP1B1* mRNA expression[@B6] and overlapped with PCa risk in the expected opposite direction suggesting potential biological consequences. Furthermore, a recent study showed that overexpression of CYP1B1 stimulated proliferative, migratory and invasive potential of non-tumorigenic PCa cells[@B21].

However, exact mechanisms of how CYP1B1 polymorphism contributes to PCa susceptibility requires further illustration. The present dataset offers an attractive possibility to address interactions between telomere length and genotypes. We hypothesized that genetic factors implicated in estrogen metabolism pathways contribute to increased oxidative stress and thereby influence telomere length. Oxidative stress causes telomere attrition by several potential pathways. Reactive oxygen species can directly damage the sensitive triple-G containing telomeres[@B22], or indirectly, act by inhibiting telomerase activity and increasing the load of pro-inflammatory cytokines that accelerate immune cell turnover and hence telomere loss[@B23]. Since estrogen metabolism is a well-known source of reactive oxygen species formation, aberrations in this pathway could compromise the redox buffering capacity of cells[@B4], which may in turn lead to increased oxidative burden and telomere attrition. Accordingly, in our study, we show for the first time that functionally relevant SNP in *CYP1B1* gene impacts telomere length in PCa patients. CYP1B1 participates in the first step of estrogen metabolism, i.e., the conversion of estrogens to 2- or 4-hydroxyestrogens, and specifically catalyzes the 4-hydroxylation of estrogens. 4-hydroxyestradiol is, in sharp contrast to 2-hydroxyestradiol, inactivated by COMT at a slower rate, and undergoes metabolic redox cycling to generate free radicals and reactive semiquinone and quionone intermediates[@B24]. The *CYP1B1* 1056836 variant allele codes for the enzyme with 2-fold higher mRNA compared to wild-type allele[@B6], leading to increased 4-hydroxyestradiol production. Consistent with this notion, telomere length was found significantly shorter in individuals carrying the CYP1B1 rs1056836 wild type allele.

A large number of intrinsic and extrinsic factors , such as heredity, epigenetics, aging, stress, immune components, and hormones are all states have been previously associated with shorter telomere length[@B25]. As such, limitations of the study are mainly related to the scarcity of the relevant exposure data and nature of retrospective study design. The current study was based on the leukocytes telomere length only and not on the prostate tissue telomere length. Because there is an intra-individual synchrony in telomere length across the somatic tissues of humans as evidenced by the strong correlations between the telomere lengths in all tissue types[@B26]. Moreover, the rates of telomere shortening are similar in the somatic tissues. However, future work aims to directly describe the relationships between prostate tissue, leukocytes telomere lengths and PCa cases. Strengths of the study include a significant number of patients, a candidate gene approach, the high plausibility of the association based on the biologic function of selected candidate genes and an impact on telomere length associated with positive markers.

In summary, significant association with PCa risk for CYP1B1 rs1056836 with telomere length may provide a biological basis for the results obtained in various studies investigating the impact of *CYP1B1* SNPs on PCa risk. With these implications, further investigation of SNP‑cancer risk associations in specific subsets of patients with particular environmental or genetic backgrounds, as well as more detailed *in vitro* and *in vivo* biological functional studies will be helpful to elucidate how exactly the *CYP1B1* genetic variations influenced PCa development.

Supplementary Material {#SM0}
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PSA

:   prostate-specific antigen

SNP

:   single nucleotide polymorphism

OR

:   odds ratio

CI

:   confidence interval.

###### 

Characteristics of PCa Cases and Controls

  --------------------------------------------------------
  Variables           Cases (%)\   Controls (%)\   *P*
                      N = 1015     N = 1052        
  ------------------- ------------ --------------- -------
  Age                 69.1 ± 8.2   68.6 ± 8.9      0.828

  ≤ 64                291 (28.7)   308 (29.3)      

  65-75               496 (48.9)   500 (47.5)      

  \> 75               228 (22.5)   244 (23.2)      

  Smoking status                                   

  Never               406 (40.0)   412 (39.2)      0.697

  Ever                609 (60.0)   640 (60.8)      

  PSA value (ng/ml)                                

  \< 10               180 (19.4)                   

  10-20               195 (21.0)                   

  \> 20               552 (59.6)                   

  Missing             88 (8.7)                     

  Gleason score                                    

  ≤ 7 (3+4)           317 (31.2)                   

  ≥ 7 (4+3)           606 (59.7)                   

  Missing             92 (9.1)                     

  Stage of disease                                 

  I                   5 (0.5)                      

  II                  434 (42.8)                   

  III                 142 (14.0)                   

  IV                  356 (35.1)                   

  Missing             78 (7.7)                     
  --------------------------------------------------------

PSA: prostate-specifc antigen

###### 

Association of *CYP1B1* SNPs with PCa Risk

  ---------------------------------------------------------------------------------
  SNP            Cases, No. (%)\   Controls, No. (%)\   OR (95% CI)        *P*^a^
                 n = 1015          n = 1052                                
  -------------- ----------------- -------------------- ------------------ --------
  rs9341266                                                                

  GG             774 (76.3)        816 (77.6)           1.00               

  AG             218(21.5)         215 (20.4)           1.07 (0.87-1.32)   0.533

  AA             23 (2.3)          21 (2.0)             1.15 (0.63-2.10)   0.649

  AG/AA vs. GG                                          1.08 (0.88-1.32)   0.477

  GG/AG vs. AA                                          1.13 (0.62-2.06)   0.683

  rs162549                                                                 

  TT             787 (77.5)        811 (77.1)           1.00               

  AT             209 (20.6)        222 (21.1)           0.95 (0.77-1.18)   0.636

  AA             19 (1.9)          19 (1.8)             1.01 (0.53-1.93)   0.971

  AT/AA vs. TT                                          0.96 (0.78-1.17)   0.660

  TT/AT vs. AA                                          1.02 (0.54-1.95)   0.944

  rs10916                                                                  

  TT             808 (79.6)        856 (81.4)           1.00               

  GT             192 (18.9)        183 (17.4)           1.12 (0.89-1.40)   0.333

  GG             15 (1.5)          13 (1.2)             0.75 (0.50-1.11)   0.152

  GT/GG vs. TT                                          1.13 (0.91-1.40)   0.289

  TT/GT vs. GG                                          1.21 (0.57-2.56)   0.617

  rs162562                                                                 

  AA             695 (68.5)        711 (67.6)           1.00               

  AC             287 (28.3)        305 (29.0)           0.97 (0.80-1.17)   0.719

  CC             33 (3.3)          36 (3.4)             0.96 (0.59-1.55)   0.854

  AC/CC vs. AA                                          0.96 (0.80-1.16)   0.700

  CC/AC vs.CC                                           0.97 (0.60-1.56)   0.887

  rs2551188                                                                

  CC             541 (53.3)        558 (53.0)           1.00               

  CT             423 (41.7)        421 (40.0)           1.05 (0.88-1.26)   0.564

  TT             51 (5.0)          73 (6.9)             0.72 (0.49-1.05)   0.086

  CT/TT vs. CC                                          1.00 (0.84-1.19)   0.964

  CC/CT vs.TT                                           0.70 (0.49-1.02)   0.060

  rs9341250                                                                

  CC             955 (94.1)        985 (93.6)           1.00               

  AC             58 (5.7)          64 (6.1)             0.96 (0.66-1.38)   0.806

  AA             2 (0.2)           3 (0.3)              0.66 (0.11-3.94)   0.644

  AC/AA vs. CC                                          0.94 (0.66-1.35)   0.741

  CC/AC vs. AA                                          0.66 (0.11-3.95)   0.646

                                                                           

  rs1056827                                                                

  CC             668 (65.8)        679 (64.5)           1.00               

  AC             303 (29.9)        327 (31.1)           0.94 (0.78-1.14)   0.543

  AA             44 (4.3)          46 (4.4)             0.98 (0.64-1.50)   0.908

  AC/AA vs. CC                                          0.95 (0.79-1.14)   0.555

  CC/AC vs. AA                                          0.99 (0.65-1.52)   0.976

  rs1056836                                                                

  CC             728 (71.7)        705 (67.0)           1.00               

  CG             274 (27.0)        323 (30.7)           0.82 (0.68-0.99)   0.041

  GG             13 (1.3)          24 (2.3)             0.54 (0.27-1.07)   0.079

  CG/GG vs. CC                                          0.80 (0.66-0.97)   0.020

  CC/CG vs. GG                                          0.57 (0.29-1.14)   0.111
  ---------------------------------------------------------------------------------

HWE: Hardy-Weinberg equilibrium. ^a^Adjusted for age and smoking status.

The results were in bold if *P* \< 0.05.

###### 

Association between *CYP1B1* SNPs and RTL

  SNP         Genotype   Short RTL, n (%)   Long RTL, n (%)   OR (95% CI)^a^     *P*
  ----------- ---------- ------------------ ----------------- ------------------ -------
  rs9341266   GG         58 (27.9)          64 (29.4)         1.00               
              AG/AA      150 (72.1)         154 (70.6)        1.08 (0.71-1.64)   0.737
  rs162549    TT         44 (21.2)          48 (22.0)         1.00               
              AT/AA      164 (78.8)         170 (78.0)        1.05 (0.66-1.67)   0.828
  rs10916     TT         35 (16.8)          54 (24.8)         1.00               
              GT/GG      173 (83.2)         164 (75.2)        1.63 (1.01-2.62)   0.045
  rs162562    AA         60 (28.8)          66 (30.3)         1.00               
              AC/CC      148 (71.2)         152 (69.7)        1.07 (0.71-1.62)   0.747
  rs2551188   CC         82 (39.4)          103 (47.2)        1.00               
              CT/TT      126 (60.6)         115 (52.8)        1.38 (0.94-2.02)   0.104
  rs9341250   CC         13 (6.2)           17 (7.8)          1.00               
              AC/AA      195 (93.8)         201 (92.2)        1.27 (0.60-2.68)   0.533
  rs1056827   CC         67 (32.2)          69 (31.7)         1.00               
              AC/AA      141 (67.8)         149 (68.3)        0.98 (0.65-1.47)   0.901
  rs1056836   CC         67 (32.2)          50 (22.9)                            
              CG/GG      141 (67.8)         168 (77.1)        1.60 (1.04-2.45)   0.033

RTL: Relative telomere length ^a^Adjusted for age and smoking status.
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